A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 29-34

  Huskisson, E C ^a,e   Ghozlan, R ^b   Kurthen, R ^c   Degner, F L ^d   Bluhmki, E ^d  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b Polyclinique de La Roseraie   (France)

^c Dr Karl Thomae GmbH ^*  (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e 14A Millford House ^*  (United Kingdom)

Author keywords

Long term; Meloxicam; NSAID; Rheumatoid arthritis

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ADULT; AGED; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; GRIP STRENGTH; HEALTH STATUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION;

EID: 0029869274     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.29     Document Type: Article

References (18)

1. Wojtulewski JA, Schattenkircher M, Barceló P et al. A six month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;35(suppl. 1):22-28.
2. Huskisson EC, Narjes H, Bluhmki E. Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30 and 60 mg in comparison with 20 mg piroxicam in patients with rheumatoid arthritis. Scand J Rheumatol 1994;Suppl 98:abstract no. 115.
3. Engelhardt G. Meloxicam: a potent inhibitor of COX-2. Data presented at the 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, June 6-10, 1994, p. 82.
4. Pincus TH, Callahan LF, Brooks RH et al. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic and laboratory measures. Ann Intern Med 1989;110:259-66.
5. Lorish CD, Abraham N, Austin J et al. Disease and psychosocial factors related to physical functioning in rheumatoid arthritis. J Rheumatol 1991;18:1150-7.
6. Ritchie DM, Boyle JA, McInners IM et al. Clinical studies with an articular index for the assessment of joint tender- ness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
7. Jones E, Hanly JG, Mooney R et al. Strength and function in the normal and rheumatoid hand. J Rheumatol 1991;18:1313-8.
8. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions Clin Pharmacol Ther 1977;21:247-54.
9. Chuang-Stein C. Summarizing laboratory data with different reference ranges in multicentre clinical trials. Drug Inf 1992;26:77-84.
10. CPMP guidelines on clinical testing requirements for drugs for long-term use. III/602/81-EN.
11. Lemmel EM, Bolten W, Burgos-Vargas R et al. A double-blind placebo controlled study of 7.5 mg and 15 mg of meloxicam in patients with rheumatoid arthritis (RA). Scand J Rheumatol 1994;Suppl 98:abstract no. 111.
12. Reginster JY, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br J Rheumatol 1996;35(suppl. 1):17-21.
13. Wijnands M, van Riel P, van't Hof M et al. Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study. J Rheumatol 1991;18:184-7.
14. Distel M, Bluhmki E. Global analysis of safety of meloxicam, a new enolic acid derived non-steroidal anti-inflammatory agent. Rheumatol Eur 1995;3:abstract no. E259.
15. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Am Intern Med 1991;114:257-63.
16. Physicians Desk Reference 1995. Medical Economics Company Inc., Montvale, NJ.
17. Kenny GNC. Potential renal, haematological and allergic adverse effects associated with nonsteroidal anti-inflammatory drugs. Drugs 1992;44:31-7.
18. Sander O, Hübner G, Türck D, et al. Differences in meloxicam pharmacokinetics in patients with chronic polyarthritis depending on sex and age. Z Rheumatol 1994;53:68 abstract no. P.113.